`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinicaltrials | British Journal of Ophthalmology
`
`Home©Archive_Volume 94, Issue 1
`
`Q =
`
`pfArticle metrics
`
`Article menu
`
`+
`
`Review
`
`Ranibizumab (Lucentis) in neovascular age-related macular
`degeneration: evidencefrom clinical trials
`
`
`Referenced in 1 policy sources
`Tweeted by 1
`Referenced in 3 patents
`[| 135 readers on Mendeley
`1 readers on CiteULike
`
`See moredetails
`
`
`
`*s==52 Field Citation Ratio
`
`9
`
`7
`
`ty
`\
`
`\
`if
`
`99
`
`250
`
`Total citations
`a.
`
`Recent citations
`# 18
`3 9.57 Relative Citation Ratio
`
`Online downloadstatistics by month:
`
`Article lifetime
`
`Last 6 months
`
`This month
`
`Online downloadstatistics by month: May 2009 to December 2020
`
`
`
`Abstract——Full Pdf
`
`May 2009
`
`326
`
`Jun 2009
`
`189
`
`Jul 2009
`
`194
`
`0
`
`0
`
`0
`
`299
`
`214
`
`130
`
`https://bjo.bmj.com/content/94/1/2_altmetrics
`
`1/12
`
`CELLTRION- EXHIBIT 1065
`
`CELLTRION - EXHIBIT 1065
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Aug 2009
`
`206
`
`Sep 2009
`
`311
`
`Oct 2009
`
`412
`
`Nov 2009
`
`330
`
`0
`
`0
`
`0
`
`0
`
`Dec 2009
`
`370
`
`11
`
`87
`
`145
`
`111
`
`110
`
`108
`
`Jan 2010
`
`406
`
`133
`
`244
`
`Feb 2010
`
`364
`
`101
`
`151
`
`Mar 2010
`
`306
`
`102
`
`137
`
`Apr 2010
`
`258
`
`51
`
`99
`
`May 2010
`
`363
`
`101
`
`149
`
`Jun 2010
`
`352
`
`Jul 2010
`
`314
`
`Aug 2010
`
`247
`
`95
`
`71
`
`98
`
`124
`
`96
`
`95
`
`Sep 2010
`
`216
`
`108
`
`109
`
`Oct 2010
`
`279
`
`96
`
`108
`
`Nov 2010
`
`330
`
`108
`
`116
`
`Dec 2010
`
`217
`
`Jan 2011
`
`224
`
`91
`
`76
`
`76
`
`92
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`2/12
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Feb 2011
`
`237
`
`Mar 2011
`
`216
`
`83
`
`81
`
`Apr 2011
`
`178
`
`116
`
`May 2011
`
`183
`
`Jun 2011
`
`134
`
`Jul 2011
`
`133
`
`Aug 2011
`
`170
`
`Sep 2011
`
`153
`
`Oct 2011
`
`146
`
`Nov 2011
`
`199
`
`Dec 2011
`
`154
`
`Jan 2012
`
`183
`
`Feb 2012
`
`196
`
`Mar 2012
`
`178
`
`Apr 2012
`
`172
`
`May 2012
`
`201
`
`Jun 2012
`
`188
`
`Jul 2012
`
`140
`
`58
`
`40
`
`32
`
`60
`
`52
`
`75
`
`69
`
`47
`
`52
`
`34
`
`34
`
`16
`
`27
`
`23
`
`30
`
`84
`
`83
`
`82
`
`80
`
`51
`
`54
`
`46
`
`77
`
`65
`
`63
`
`40
`
`45
`
`45
`
`53
`
`39
`
`56
`
`43
`
`54
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`3/12
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Aug 2012
`
`152
`
`Sep 2012
`
`170
`
`Oct 2012
`
`168
`
`Nov 2012
`
`161
`
`Dec 2012
`
`171
`
`Jan 2013
`
`176
`
`Feb 2013
`
`873
`
`Mar 2013
`
`153
`
`Apr 2013
`
`189
`
`May 2013
`
`145
`
`Jun 2013
`
`115
`
`Jul 2013
`
`99
`
`Aug 2013
`
`81
`
`Sep 2013
`
`103
`
`Oct 2013
`
`79
`
`Nov 2013
`
`120
`
`Dec 2013
`
`68
`
`Jan 2014
`
`105
`
`32
`
`20
`
`53
`
`30
`
`25
`
`18
`
`34
`
`20
`
`24
`
`18
`
`20
`
`31
`
`20
`
`27
`
`41
`
`25
`
`6
`
`15
`
`58
`
`42
`
`33
`
`43
`
`38
`
`37
`
`41
`
`28
`
`38
`
`27
`
`31
`
`35
`
`25
`
`28
`
`33
`
`41
`
`10
`
`24
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`4/12
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Feb 2014
`
`118
`
`Mar 2014
`
`80
`
`Apr 2014
`
`120
`
`May 2014
`
`116
`
`Jun 2014
`
`Jul 2014
`
`78
`
`83
`
`Aug 2014
`
`58
`
`Sep 2014
`
`Oct 2014
`
`60
`
`68
`
`Nov 2014
`
`57
`
`Dec 2014
`
`Jan 2015
`
`Feb 2015
`
`Mar 2015
`
`Apr 2015
`
`60
`
`65
`
`67
`
`67
`
`60
`
`May 2015
`
`49
`
`Jun 2015
`
`Jul 2015
`
`35
`
`46
`
`14
`
`16
`
`11
`
`20
`
`15
`
`13
`
`6
`
`17
`
`12
`
`20
`
`11
`
`8
`
`9
`
`7
`
`17
`
`7
`
`9
`
`18
`
`28
`
`19
`
`18
`
`27
`
`20
`
`16
`
`11
`
`20
`
`21
`
`21
`
`17
`
`15
`
`11
`
`11
`
`19
`
`10
`
`30
`
`6
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`5/12
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Aug 2015
`
`56
`
`Sep 2015
`
`Oct 2015
`
`66
`
`62
`
`Nov 2015
`
`43
`
`Dec 2015
`
`Jan 2016
`
`Feb 2016
`
`Mar 2016
`
`Apr 2016
`
`59
`
`51
`
`58
`
`54
`
`49
`
`May 2016
`
`55
`
`Jun 2016
`
`Jul 2016
`
`50
`
`37
`
`Aug 2016
`
`50
`
`Sep 2016
`
`Oct 2016
`
`53
`
`45
`
`Nov 2016
`
`58
`
`Dec 2016
`
`Jan 2017
`
`37
`
`37
`
`4
`
`10
`
`7
`
`10
`
`9
`
`8
`
`6
`
`7
`
`11
`
`5
`
`5
`
`9
`
`10
`
`13
`
`3
`
`5
`
`7
`
`5
`
`8
`
`9
`
`10
`
`16
`
`7
`
`12
`
`8
`
`11
`
`13
`
`11
`
`8
`
`7
`
`7
`
`13
`
`5
`
`4
`
`61
`
`37
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`6/12
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Feb 2017
`
`Mar 2017
`
`Apr 2017
`
`42
`
`56
`
`27
`
`May 2017
`
`56
`
`Jun 2017
`
`Jul 2017
`
`75
`
`83
`
`Aug 2017
`
`169
`
`Sep 2017
`
`212
`
`Oct 2017
`
`283
`
`Nov 2017
`
`143
`
`Dec 2017
`
`175
`
`Jan 2018
`
`180
`
`Feb 2018
`
`177
`
`Mar 2018
`
`171
`
`Apr 2018
`
`174
`
`May 2018
`
`174
`
`Jun 2018
`
`150
`
`Jul 2018
`
`173
`
`7
`
`6
`
`15
`
`18
`
`4
`
`5
`
`16
`
`12
`
`10
`
`16
`
`61
`
`55
`
`59
`
`47
`
`63
`
`44
`
`66
`
`88
`
`6
`
`7
`
`8
`
`16
`
`4
`
`5
`
`22
`
`11
`
`10
`
`7
`
`4
`
`11
`
`3
`
`6
`
`16
`
`5
`
`13
`
`5
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`7/12
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Aug 2018
`
`194
`
`Sep 2018
`
`237
`
`Oct 2018
`
`224
`
`Nov 2018
`
`243
`
`Dec 2018
`
`188
`
`Jan 2019
`
`193
`
`Feb 2019
`
`147
`
`Mar 2019
`
`109
`
`Apr 2019
`
`113
`
`May 2019
`
`134
`
`Jun 2019
`
`183
`
`Jul 2019
`
`128
`
`Aug 2019
`
`163
`
`Sep 2019
`
`131
`
`Oct 2019
`
`120
`
`Nov 2019
`
`139
`
`Dec 2019
`
`231
`
`Jan 2020
`
`128
`
`74
`
`81
`
`53
`
`45
`
`51
`
`48
`
`45
`
`9
`
`10
`
`28
`
`53
`
`41
`
`48
`
`53
`
`46
`
`35
`
`50
`
`44
`
`1
`
`4
`
`11
`
`11
`
`3
`
`8
`
`6
`
`3
`
`9
`
`3
`
`8
`
`6
`
`4
`
`9
`
`2
`
`1
`
`3
`
`8
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`8/12
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Feb 2020
`
`149
`
`Mar 2020
`
`117
`
`Apr 2020
`
`147
`
`May 2020
`
`149
`
`Jun 2020
`
`182
`
`Jul 2020
`
`128
`
`Aug 2020
`
`76
`
`Sep 2020
`
`139
`
`Oct 2020
`
`128
`
`Nov 2020
`
`88
`
`Dec 2020
`
`146
`
`47
`
`56
`
`59
`
`65
`
`53
`
`46
`
`33
`
`50
`
`44
`
`4
`
`33
`
`6
`
`7
`
`8
`
`3
`
`3
`
`5
`
`2
`
`2
`
`2
`
`5
`
`5
`
`Total
`
`21684
`
`4890
`
`5346
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`9/12
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`bmjcareers
`
`Consultant Ophthalmologist
`Crewe, Cheshire
`
`Applications are invited for a Consultant Ophthalmologist at Mid Cheshire Hospitals NHS Foundation Trust
`
`Recruiter: Mid Cheshire Hospitals NHS Foundation Trust
`
`Apply for this job
`
`Clinical Teaching Fellow CT1-3
`Dundee, Dundee City
`
`NHSTayside have a vacancy for a Teaching Fellow (CT 1-3 level) in Otolaryngology, Ophthalmology and Plastic Surgery
`
`Recruiter: NHS Tayside
`
`Apply for this job
`
`Consultant Adnexal & Digital Medicine
`London(Central), London (Greater) Consultant £82,096- £110,683 per annum,pro rata
`
`Opportunity for Consultant who has experience in Adnexal Surgery & working with Digital Clinical teams &
`leadership/managementexperience
`
`Recruiter: Moorfields Eye Hospital NHS Foundation Trust
`
`Apply for this job
`
`SeniorTraining Fellow in Ophthalmology
`Stafford, Staffordshire
`N/A
`
`Other content recommendedfor you
`
`Notion of tolerating subretinal fluid in neovascular AMD: understanding thefine prints before the
`injection pause
`Ashish Sharmaetal., Br J Ophthalmol, 2020
`
`Updatedclassification and managementof pulmonary hypertension
`Holger M Nefet al., Heart, 2010
`
`Maculardysfunction in patients with macula-on rhegmatogenousretinal detachments
`Kunihiko Akiyamaet al., Br J Ophthalmol, 2019
`
`Fluid-based prognostication in n-AMD: Type 3 macular neovascularisation needs an analysis in
`isolation
`
`Ashish Sharmaetal., Br J Ophthalmol, 2020
`
`rrection: The development of assessment of SpondyloArthritis international society classification
`.{teria for axial spondyloarthritis (part Il): validation and final selection
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`10/12
`
`
`
`1/19/2021
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinicaltrials | British Journal of Ophthalmology
`
`BMJ Publishing Group Ltd and European League Against Rheumatism, Ann Rheum Dis, 2019
`
`Cheer Up, Pharma Researchers. You Could Be Working in the Auto Industry @
`GenomeWeb, 2007
`
`Bayer Schering Pharma RenewsLicense for GeneGos MetaCore 7
`GenomeWeb, 2009
`Annan mam thn Darfaersannan mt Dislernnnans Diam atian Tanta far Data atinn af I Din Diffisnn Cristamnnaniin
`
`CONTENT
`
`Latest content
`
`Currentissue
`
`Archive
`
`Browseby topic
`
`Most read articles
`
`Responses
`
`JOURNAL
`
`About
`
`Editorial board
`
`Sign up for email alerts
`
`Subscribe
`
`Thank you to our reviewers
`
`AUTHORS
`
`Instructions for authors
`
`Submit an article
`
`Editorial policies
`
`OpenAccessat BMJ
`
`BM) Author Hub
`
`https://bjo.bmj.com/content/94/1/2_altmetrics
`
`11/12
`
`
`
`1/19/2021
`HELP
`
`Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials | British Journal of Ophthalmology
`
`Contact us
`
`Reprints
`
`Permissions
`
`Advertising
`
`Feedback form
`
`
`
`Website Terms & Conditions
`Privacy & Cookies
`Contact BMJ
`
`Cookie settings
`
`Online: ISSN 1468-2079
`
`Print: ISSN 0007-1161
`Copyright © 2020 BMJ Publishing Group Ltd. All rights reserved.
`京ICP备15042040号-3
`
`https://bjo.bmj.com/content/94/1/2.altmetrics
`
`12/12
`
`